Search Results

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, “Iveric Bio”) with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the “Acquisition”).

Astellas Pharma Inc. and Iveric bio, Inc. announced that on April 29, 2023, the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$40.00 per share in cash for a total equity value of approximately US$5.9 billion.

IVERIC bio, Inc. reported that on July 3, 2023, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to 23 newly-hired, non-executive employees.

About a month after reporting it’s had a tough time starting enough patients on its treatments, bluebird bio announced it will lay off about 25% of its employees, over half of whom work in R&D.

IVERIC bio, Inc. announced that Iveric Bio management will participate in fireside chats at the following investor conferences in November.

With the addition of NTx’s co-founder and former President to the board Mercury Bio significantly enhances its strategic reach in the biotech sector

IVERIC bio, Inc. reported that on May 19, 2023, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to three newly-hired, non-executive employees.

IVERIC bio, Inc. (Nasdaq: ISEE) announced today the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023.

IVERIC bio, Inc. reported that on May 19, 2023, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to 63 newly-hired, non-executive employees.

Japanese biopharma scoops up Iveric’s investigational drug for age-related blindness disease. The drug, which trails Apellis’ Syfovre, is awaiting FDA approval with a decision expected by August.